EA201270345A1 - Модифицированный фрагмент агрина, способный восстанавливать мышечную силу, для применения в качестве лекарства - Google Patents

Модифицированный фрагмент агрина, способный восстанавливать мышечную силу, для применения в качестве лекарства

Info

Publication number
EA201270345A1
EA201270345A1 EA201270345A EA201270345A EA201270345A1 EA 201270345 A1 EA201270345 A1 EA 201270345A1 EA 201270345 A EA201270345 A EA 201270345A EA 201270345 A EA201270345 A EA 201270345A EA 201270345 A1 EA201270345 A1 EA 201270345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medicine
agrine
muscle power
modified
restore muscle
Prior art date
Application number
EA201270345A
Other languages
English (en)
Other versions
EA026814B1 (ru
Inventor
Стефан Хеттвер
Стефан Кукзера
Ян Виллем Врейблуд
Original Assignee
Нейротьюн Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейротьюн Аг filed Critical Нейротьюн Аг
Publication of EA201270345A1 publication Critical patent/EA201270345A1/ru
Publication of EA026814B1 publication Critical patent/EA026814B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Модифицированный фрагмент агрина, обладающий активностью in vivo, содержащий по меньшей мере домены LG2 и LG3 агрина человека в ковалентно связанной форме, и модифицированный таким образом, что фрагмент не может быть расщеплен нейротрипсином, для применения в качестве лекарства.
EA201270345A 2009-09-04 2010-09-01 Применение модифицированного фрагмента агрина, способного восстанавливать мышечную силу, для изготовления лекарства EA026814B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09011367A EP2295068A1 (en) 2009-09-04 2009-09-04 Modified agrin-fragment capable of restoring muscle strength for use as a medicament
PCT/EP2010/005372 WO2011026615A1 (en) 2009-09-04 2010-09-01 Modified agrin-fragment capable of restoring muscle strength for use as a medicament

Publications (2)

Publication Number Publication Date
EA201270345A1 true EA201270345A1 (ru) 2012-09-28
EA026814B1 EA026814B1 (ru) 2017-05-31

Family

ID=41278553

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270345A EA026814B1 (ru) 2009-09-04 2010-09-01 Применение модифицированного фрагмента агрина, способного восстанавливать мышечную силу, для изготовления лекарства

Country Status (16)

Country Link
US (1) US8685915B2 (ru)
EP (3) EP2295068A1 (ru)
JP (1) JP5752124B2 (ru)
KR (1) KR20120060878A (ru)
CN (1) CN102481339B (ru)
AU (1) AU2010291560B2 (ru)
BR (1) BR112012008104B1 (ru)
CA (1) CA2769602A1 (ru)
DK (2) DK2473184T3 (ru)
EA (1) EA026814B1 (ru)
ES (2) ES2743239T3 (ru)
HK (1) HK1167092A1 (ru)
IL (1) IL217741A0 (ru)
MX (1) MX2012001409A (ru)
NZ (1) NZ597853A (ru)
WO (1) WO2011026615A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484695A1 (en) * 2011-02-04 2012-08-08 Neurotune AG A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human C44-fragment of agrin
CN103869078A (zh) * 2014-03-04 2014-06-18 南昌大学 利用聚集蛋白针对神经传递障碍疾病的诊断组合物
EP3128326B1 (en) * 2014-04-03 2018-03-14 Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Biomarker for diagnosis of aging or amyotrophia
IL242380A0 (en) * 2015-10-29 2016-02-01 Yeda Res & Dev A method for inducing the division of cardiomyocytes and treating heart diseases
GB201620119D0 (en) * 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
EP3634495A4 (en) * 2017-06-01 2021-02-24 Baylor College of Medicine DYSTROPHIN GLYCOPROTEIN COMPLEX FOR THE SEQUESTRATION OF YAP FOR THE INHIBITION OF CARDIOMYOCYTE PROLIFERATION
EP3716993A1 (en) * 2017-12-03 2020-10-07 Yeda Research and Development Co. Ltd Treatment of an ischemic heart disease
WO2023165925A1 (en) * 2022-03-02 2023-09-07 Universität Basel Novel proteins and nucleic acid sequences and use thereof in the prophylaxis and/or treatment of congenital muscular dystrophies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814478A (en) * 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US20080295186A1 (en) * 1998-04-24 2008-11-27 Peter Sonderegger Neurotrypsin overexpressing animal
AU2006228150B2 (en) * 2005-03-30 2011-09-29 University Of Zurich Inhibitors of neurotrypsin and determination thereof
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases

Also Published As

Publication number Publication date
EP2473184A1 (en) 2012-07-11
EP3050569B1 (en) 2019-05-29
EP3050569A1 (en) 2016-08-03
NZ597853A (en) 2014-04-30
ES2572835T3 (es) 2016-06-02
BR112012008104B1 (pt) 2019-12-03
ES2743239T3 (es) 2020-02-18
DK2473184T3 (en) 2016-06-13
KR20120060878A (ko) 2012-06-12
DK3050569T3 (da) 2019-09-02
AU2010291560B2 (en) 2016-09-29
US20120208765A1 (en) 2012-08-16
JP2013503825A (ja) 2013-02-04
IL217741A0 (en) 2012-03-29
BR112012008104A2 (pt) 2016-09-13
CA2769602A1 (en) 2011-03-10
EP2473184B1 (en) 2016-03-02
AU2010291560A1 (en) 2012-02-16
CN102481339B (zh) 2015-01-14
CN102481339A (zh) 2012-05-30
EA026814B1 (ru) 2017-05-31
US8685915B2 (en) 2014-04-01
MX2012001409A (es) 2012-05-23
EP2295068A1 (en) 2011-03-16
WO2011026615A1 (en) 2011-03-10
JP5752124B2 (ja) 2015-07-22
HK1167092A1 (en) 2012-11-23

Similar Documents

Publication Publication Date Title
EA201270345A1 (ru) Модифицированный фрагмент агрина, способный восстанавливать мышечную силу, для применения в качестве лекарства
CY1123404T1 (el) Αντι-girt αντισωματα
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
ATE474585T1 (de) Probiotische enterokokken für eine verbesserte immunität
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
EA201001372A1 (ru) Формы рифаксимина и их применение
EA201791850A1 (ru) Борсодержащие малые молекулы
UY31484A1 (es) Piperidinas heteroaril-sustituidas
BRPI0911594A2 (pt) di-hidropirazolonas substistuídas, seu processo de preparação e seu uso, bem como medicamentos
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
ATE532814T1 (de) Neue ammonium-polyurethan- und/oder polycarbonat- verbindungen
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EA200970816A1 (ru) Новая лекарственная форма
EA201000864A1 (ru) Фенилоксетанильные производные
NZ598124A (en) Compounds for treatment of inflammation
CY1111328T1 (el) Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG